Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

MPS VI (Maroteaux-Lamy syndrome): the short answer

The US FDA has approved one medicine on this page for MPS VI (Maroteaux-Lamy syndrome), each for specific patients. One of them is on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Naglazyme.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is MPS VI (Maroteaux-Lamy syndrome)?

Mucopolysaccharidosis type VI (MPS VI), also called Maroteaux-Lamy syndrome, is a progressive condition that causes many tissues and organs to enlarge, become inflamed or scarred, and waste away. How fast it worsens varies.^[1]

Children usually show signs in early childhood. Features include a large head, coarse facial features, a large tongue, short stature, joint stiffness, skeletal changes, carpal tunnel syndrome, heart valve problems, narrow airways with sleep apnea, an enlarged liver and spleen, clouding of the cornea and hearing loss.^[1]

MPS VI is an autosomal recessive condition caused by deficiency of the enzyme arylsulfatase B. Care is led by metabolic specialists, and in the US an enzyme replacement therapy is approved for patients with MPS VI.^{[2, 3]}

MPS VI (Maroteaux-Lamy syndrome) in the Gulf

A review at the main hospital in Saudi Arabia's Eastern Province identified 18 patients with MPS VI from 6 families over 33 years, all with first-cousin parents and the severe form. Five families from the Al-Hofuf area shared the same gene variant.^[2]

US FDA-approved medicines for MPS VI (Maroteaux-Lamy syndrome)

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Naglazyme (galsulfase)
FDA-approved for patients with MPS VI (Maroteaux-Lamy syndrome). It is an enzyme replacement therapy given by intravenous infusion.^[3]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for MPS VI (Maroteaux-Lamy syndrome)

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for MPS VI (Maroteaux-Lamy syndrome)?

Yes. The medicine on this page has US FDA approval for specific groups of patients: Naglazyme. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Naglazyme available in Saudi Arabia or the UAE?

Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Naglazyme?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Why does a shared gene variant matter for families?

The Eastern Province study found the same variant in several related families. That helps doctors with testing and genetic counseling for relatives. Ask your specialist about family screening.

Is MPS VI the same as Morquio syndrome?

No. They are different types of mucopolysaccharidosis caused by different enzymes. MPS VI is caused by arylsulfatase B deficiency.

Sources for the last two answers: ^[2] ^[2]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.